MAGEA1 and laryngotracheoesophageal cleft: [21] Recently, a seven-AAB panel (p53, PGP9.5, SOX2, GAGE7, GBU4-5, CAGE, and MAGEA1) was developed and commoditized in China, which is mainly used as a new biomarker in the early diagnosis of lung cancer, with a sensitivity range from 56.5% to 62% and a specificity range from 90% to 91.6% in the detection of early-stage LC.